The expanding role of vascular endothelial growth factor inhibitors in ophthalmology.
about
Vascular endothelial growth factor inhibitors: investigational therapies for the treatment of psoriasisDiabetic Macular Edema Pathophysiology: Vasogenic versus InflammatoryVascular permeability--the essentialsLong-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edemaSYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB.Local acting Sticky-trap inhibits vascular endothelial growth factor dependent pathological angiogenesis in the eye.The effects of technological advances on outcomes for elderly persons with exudative age-related macular degeneration.Effects of 5-aza-2'-deoxycytidine and trichostatin A on high glucose- and interleukin-1β-induced secretory mediators from human retinal endothelial cells and retinal pigment epithelial cellsEffects of a single intravitreal injection of aflibercept and ranibizumab on glomeruli of monkeysChoosing preclinical study models of diabetic retinopathy: key problems for considerationComparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degeneration.Treatment of retinopathy of prematurity: a review of conventional and promising new therapeutic optionsCritical appraisal of ranibizumab in the treatment of diabetic macular edema.Exploring leptin antagonism in ophthalmic cell modelsOptical coherence tomographic and visual results at six months after transitioning to aflibercept for patients on prior ranibizumab or bevacizumab treatment for exudative age-related macular degeneration (an American Ophthalmological Society thesis)The ABCs of RVO: a review of retinal venous occlusion.Intravitreal injection of bevacizumab for retinopathy of prematurity.Omega-3 supplementation combined with anti-vascular endothelial growth factor lowers vitreal levels of vascular endothelial growth factor in wet age-related macular degenerationEvaluation of anti-HIF and anti-angiogenic properties of honokiol for the treatment of ocular neovascular diseases.Comparison of two anesthetic methods for intravitreal ozurdex injectionIntravitreal aflibercept (Eylea) injection for cystoid macular edema secondary to retinitis pigmentosa - a first case report and short review of the literatureAflibercept: A Review of Its Use in Diabetic Macular Oedema.Role of salivary vascular endothelial growth factor (VEGF) in palatal mucosal wound healing.Intravitreal dobesilate in the treatment of choroidal neovascularisation associated with age-related macular degeneration: report of two cases.Dramatic response to inhaled dobesilate in a patient with lung squamous cell cancer.Treatment of Stargardt disease with dobesilate.Optical Coherence Tomography Monitoring Strategies for A-VEGF-Treated Age-Related Macular Degeneration: An Evidence-Based AnalysisDesigner Leptin Receptor Antagonist Allo-aca Inhibits VEGF Effects in Ophthalmic Neoangiogenesis Models.Aflibercept: A Review in Macular Oedema Secondary to Branch Retinal Vein Occlusion.Antiangiogenic and Neurogenic Activities of Sleeping Beauty-Mediated PEDF-Transfected RPE Cells In Vitro and In VivoA novel small molecule ameliorates ocular neovascularisation and synergises with anti-VEGF therapyAflibercept in wet AMD: specific role and optimal use.Pharmacokinetics of bevacizumab after topical and intravitreal administration in human eyes.Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration.Aflibercept for intravitreal injection: in neovascular age-related macular degeneration.Aflibercept (VEGF Trap-Eye) for the treatment of exudative age-related macular degeneration.Ranibizumab: a review of its use in the treatment of neovascular age-related macular degeneration.In vitro and ex vivo retina angiogenesis assays.Intravitreal aflibercept (Eylea(®)): a review of its use in patients with macular oedema secondary to central retinal vein occlusion.Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration: an overview.
P2860
Q22305863-B333FA59-56D0-43E4-A0AA-BFA71FD53C6BQ28070894-E88ED66B-8B49-49D5-B11E-2B8D6D11727DQ28085112-8D0D837A-E958-4D62-9FD7-71B9219FB0BFQ28292764-28D0EA98-C190-4C50-B6FC-19C7A6911A3EQ30490738-FBAE6167-7431-43D7-8825-668AF4BB1C77Q33623357-961F73D3-F869-4DBC-B469-474A4CA39F77Q34158108-EC26FF58-E01C-4C25-A52B-EB9A2CE9A449Q34249929-4F574756-CBAA-4181-8B2F-0A25DCBA2883Q34557530-F2D3E9DE-5454-4B09-951C-A8BFF0D1C079Q34564352-0BF92BC0-60BD-45A1-9C9A-7C43A38FFC95Q34624487-434F8FDD-7276-48F1-AEEC-18AAE3B6504AQ34704214-1C937689-3755-4359-8850-A8858E216D2EQ34803171-B0E96C3D-4563-4114-86D2-D9243DC8DB91Q35009436-5F37A1D1-7B15-4667-9AAD-76071BB4B6A1Q35016867-862163E8-2CC8-4995-A26D-7F3D4CA243D6Q35047634-25466078-7619-4C27-B716-43752523DD82Q35102460-D55039C8-E1D9-4AA7-BD92-FF04B6A12060Q35316532-82B7FEF5-9150-48E2-A6DC-E9967AFB48C2Q35448249-7F0A6682-AD2B-492F-A569-B4AD5521FB94Q35531482-827358AA-C670-47A0-8FD0-D4570C9696E3Q35618296-14C42D08-C04B-4D33-8A23-A6D255810205Q35657595-369EE666-8E9F-4059-91D7-0F07D1277FAAQ35925996-760DA74D-D520-46B0-8F79-7C2FDE580C42Q35977309-B9C5FD83-87D3-4456-B227-49206CA52F4AQ35979621-AA86BC03-24DC-4C3C-BCAA-7C62684DDA89Q35979853-036D00C7-61E0-4F10-AC98-3DC265EF0CCCQ35996271-FF9A2D70-5A51-43B1-906A-1CAAB8A8EDD6Q36176814-48DF2A70-759C-4316-A33D-E875840C887CQ36331045-7B8EE48C-F577-4631-B280-923076F39540Q36369034-6A756C42-9131-49CA-9A36-428BF958F551Q36872704-D8E013A8-4C21-4EBF-B145-F39EBBF788E8Q37109788-6C6E65CB-85C7-4846-9259-4BA66DA11B39Q37549985-F216FBF5-8648-4C0B-B864-5997EEE29A54Q38032311-CFF48960-DA04-4295-83EE-075744F34E34Q38049556-42CA44C3-5AB8-489A-A2F2-8473921E152FQ38087692-82862872-271D-4708-AC5D-12506411A82EQ38094076-40E79430-4480-4E73-B82C-A2E33EB4C110Q38152261-04D873A2-1C42-48C3-91EB-AE39900BF646Q38205131-D0ADE4C2-755F-4F08-9904-7108C230A594Q38210239-1570B0C3-2E63-4A10-B859-7CFA8EAC6527
P2860
The expanding role of vascular endothelial growth factor inhibitors in ophthalmology.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
The expanding role of vascular endothelial growth factor inhibitors in ophthalmology.
@ast
The expanding role of vascular endothelial growth factor inhibitors in ophthalmology.
@en
The expanding role of vascular endothelial growth factor inhibitors in ophthalmology.
@nl
type
label
The expanding role of vascular endothelial growth factor inhibitors in ophthalmology.
@ast
The expanding role of vascular endothelial growth factor inhibitors in ophthalmology.
@en
The expanding role of vascular endothelial growth factor inhibitors in ophthalmology.
@nl
prefLabel
The expanding role of vascular endothelial growth factor inhibitors in ophthalmology.
@ast
The expanding role of vascular endothelial growth factor inhibitors in ophthalmology.
@en
The expanding role of vascular endothelial growth factor inhibitors in ophthalmology.
@nl
P2860
P1476
The expanding role of vascular endothelial growth factor inhibitors in ophthalmology.
@en
P2093
Michael W Stewart
P2860
P356
10.1016/J.MAYOCP.2011.10.001
P407
P577
2012-01-01T00:00:00Z